Paul Chaplin, President & CEO of Bavarian Nordic, said: "Upon the successful approvals earlier this year of our chikungunya vaccine for persons aged 12 and older, we are pleased to initiate this ...

As for Bavarian Nordic, the vaccine specialist is differentiating itself from rival Valneva not only when it comes to PRV sale prices. In May, the FDA and the CDC recommended a pause in the use of ...

Sale prices for the vouchers – which slash FDA review times for a drug – have increased in the past year as biotech funding ...

Bavarian Nordic has commenced a Phase III trial of its chikungunya vaccine, CHIKV VLP, targeting the paediatric population aged two to 11 years old. This marks the first study of the single-dose ...

It was only in February 2024 that Valneva monetized a PRV obtained from the FDA approval of the U.S.’s first approved chikungunya vaccine, Ixchiq, for $103 million. The general understanding at ...

Bavarian Nordic was awarded the PRV in February 2025, following the approval by the U.S. Food and Drug Administration of the chikungunya vaccine, VIMKUNYA for prevention of disease caused by ...

The EMA's human medicines committee has recommended approval for Bavarian Nordic's chikungunya vaccine, which is shaping up to be the first alternative to a rival shot from Valneva. The CHIKV VLP ...

Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of USD 160 million. Bavarian Nordic was ...

Bavarian Nordic was awarded the PRV in February 2025, following the approval by the U.S. Food and Drug Administration of the chikungunya vaccine, VIMKUNYA™ for prevention of disease caused by ...

Paul Chaplin, President & CEO of Bavarian Nordic, said: “Upon the successful approvals earlier this year of our chikungunya vaccine for persons aged 12 and older, we are pleased to initiate this Phase ...